Home › Compare › DMET vs MRK

DMET vs MRK: Dividend Comparison 2026

DMET yields 1197604.79% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMET wins by $2.893352326641223e+37M in total portfolio value
10 years
DMET
DMET
● Live price
1197604.79%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.893352326641223e+37M
Annual income
$28,928,771,509,188,626,000,000,000,000,000,000,000,000,000.00
Full DMET calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — DMET vs MRK

📍 DMET pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMETMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMET + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DMET pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMET
Annual income on $10K today (after 15% tax)
$101,796,407.19/yr
After 10yr DRIP, annual income (after tax)
$24,589,455,782,810,330,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, DMET beats the other by $24,589,455,782,810,330,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMET + MRK for your $10,000?

DMET: 50%MRK: 50%
100% MRK50/50100% DMET
Portfolio after 10yr
$1.4466761633206116e+37M
Annual income
$14,464,385,754,594,313,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

DMET
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMET buys
0
MRK buys
0
No recent congressional trades found for DMET or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMETMRK
Forward yield1197604.79% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$2.893352326641223e+37M$30.7K ✓
Annual income after 10y$28,928,771,509,188,626,000,000,000,000,000,000,000,000,000.00 ✓$950.29
Total dividends collected$2.8933212359191986e+37M$6.1K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DMET vs MRK ($10,000, DRIP)

YearDMET PortfolioDMET Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$119,771,179$119,760,479.04$11,192$351.54+$119.76M → DMET
2$1,340,675,237,169$1,340,547,082,007.01$12,524$392.70+$1340675.22M → DMET
3$14,025,358,764,179,386$14,023,924,241,675,614.00$14,015$438.65+$14025358764.17M → DMET
4$137,127,229,670,789,460,000$137,112,222,536,911,770,000.00$15,682$489.96+$137127229670789.45M → DMET
5$1,253,005,492,090,078,200,000,000$1,252,858,765,954,330,400,000,000.00$17,547$547.23+$1253005492090078208.00M → DMET
6$10,700,449,682,072,446,000,000,000,000$10,699,108,966,195,910,000,000,000,000.00$19,632$611.16+$1.0700449682072447e+22M → DMET
7$85,402,604,415,157,980,000,000,000,000,000$85,391,154,933,998,160,000,000,000,000,000.00$21,963$682.53+$8.540260441515798e+25M → DMET
8$637,030,900,017,999,260,000,000,000,000,000,000$636,939,519,231,275,000,000,000,000,000,000,000.00$24,571$762.18+$6.370309000179992e+29M → DMET
9$4,440,894,601,502,973,000,000,000,000,000,000,000,000$4,440,212,978,439,954,000,000,000,000,000,000,000,000.00$27,486$851.08+$4.440894601502973e+33M → DMET
10$28,933,523,266,412,233,000,000,000,000,000,000,000,000,000$28,928,771,509,188,626,000,000,000,000,000,000,000,000,000.00$30,745$950.29+$2.893352326641223e+37M → DMET

DMET vs MRK: Complete Analysis 2026

DMET — Stock

DMET is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in DMET shares.

Full DMET Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this DMET vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMET vs SCHDDMET vs JEPIDMET vs ODMET vs KODMET vs MAINDMET vs JNJDMET vs ABBVDMET vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.